Scios Announces Strong Initial Natrecor Sales
SUNNYVALE, Calif., Oct. 1 /PRNewswire/ -- Scios Inc. (Nasdaq: SCIO) announced today that it has recorded net sales of $4.5 million for Natrecor(R) (nesiritide), in the third quarter ended September 30, 2001. This sales level indicates strong initial acceptance of Scios' recently launched flagship product especially in light of the August 15th launch date and only six weeks of selling activity during the 13 weeks of the quarter. Scios expects to report its full third quarter 2001 financial results on Thursday, October 25, 2001.
"We are very pleased with the positive experiences physicians and their patients are having with Natrecor in hospitals across the country," said Tom Feldman, Vice President of Sales and Marketing at Scios. "Our sales force is making an immediate impact with our target customers."
Scios began marketing Natrecor on August 15, 2001 through its 168 person sales force, immediately after receiving FDA approval. Of the 2,000 hospitals Scios is targeting, Natrecor is now available in approximately 500 U.S. hospitals, and the company is already receiving numerous re-orders.
"Based on what we saw in just six weeks, we are comfortable with our Natrecor sales projections of $10 - $12 million for 2001," said Richard B. Brewer, President and Chief Executive Officer of Scios. "We will continue to roll out our marketing and educational programs to support Natrecor and believe the programs will significantly enhance our sales penetration into 2002."
Natrecor is the first of a new class of drugs, called human B-type natriuretic peptides (hBNP), available for use in the United States. Natrecor is a recombinant form of hBNP, a natural protein produced by the heart.
Third Quarter Conference Call Details
Scios will host its customary quarterly conference call on Thursday, October 25, 2001, at 7:00 a.m. PT/10:00 a.m. ET to discuss the results of the quarter and the company's outlook. The dial-in number is 800-364-4174, confirmation code 1933643. The call will also be broadcast live and archived on Scios' web site at sciosinc.com until November 1, 2001.
Scios Inc.
Scios is a biopharmaceutical company developing novel treatments for cardiovascular and inflammatory disease. The Company's disease-based technology platform integrates expertise in protein biology with computational and medicinal chemistry to identify novel targets and rationally design small molecule compounds for large markets with unmet medical needs.
Forward-Looking Safe Harbor Disclaimer
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. We generally identify such forward-looking statements using words like "believe," "intend," "expect," "may," "should," "plan," "project," "contemplate," "anticipate" or similar statements. Statements that are not historical facts are forward-looking statements based on current assumptions that involve risks and uncertainties. These risks and uncertainties may include the sales penetration and success of Natrecor, the success of clinical trials of our pipeline products, including SCIO-469, as well as other risks detailed from time to time in the reports filed by Scios with the SEC, including the Company's quarterly reports and annual report on Form 10-K. Actual results, performance or achievements of Scios may differ significantly from those described in these forward-looking statements. Scios disclaims any intention or obligation to update or revise any financial projections or forward-looking statements, whether as a result of new information, future events or otherwise.
MAKE YOUR OPINION COUNT - Click Here
tbutton.prnewswire.com
SOURCE Scios Inc.
CO: Scios Inc.
ST: California
IN: MTC BIO
SU: SLS CCA
10/01/2001 16:35 EDT prnewswire.com |
